164 related articles for article (PubMed ID: 32070762)
1. Crystallization tendency of APIs possessing different thermal and glass related properties in amorphous solid dispersions.
Kapourani A; Vardaka E; Katopodis K; Kachrimanis K; Barmpalexis P
Int J Pharm; 2020 Apr; 579():119149. PubMed ID: 32070762
[TBL] [Abstract][Full Text] [Related]
2. Rivaroxaban polymeric amorphous solid dispersions: Moisture-induced thermodynamic phase behavior and intermolecular interactions.
Kapourani A; Vardaka E; Katopodis K; Kachrimanis K; Barmpalexis P
Eur J Pharm Biopharm; 2019 Dec; 145():98-112. PubMed ID: 31698042
[TBL] [Abstract][Full Text] [Related]
3. Preparation and Evaluation of Amorphous Solid Dispersions for Enhancing Luteolin's Solubility in Simulated Saliva.
Koromili M; Kapourani A; Barmpalexis P
Polymers (Basel); 2022 Dec; 15(1):. PubMed ID: 36616519
[TBL] [Abstract][Full Text] [Related]
4. Enhanced kinetic solubility profiles of indomethacin amorphous solid dispersions in poly(2-hydroxyethyl methacrylate) hydrogels.
Sun DD; Ju TC; Lee PI
Eur J Pharm Biopharm; 2012 May; 81(1):149-58. PubMed ID: 22233548
[TBL] [Abstract][Full Text] [Related]
5. Experimental, Thermodynamic, and Molecular Modeling Evaluation of Amorphous Simvastatin-Poly(vinylpyrrolidone) Solid Dispersions.
Kapourani A; Chatzitheodoridou M; Kontogiannopoulos KN; Barmpalexis P
Mol Pharm; 2020 Jul; 17(7):2703-2720. PubMed ID: 32520564
[TBL] [Abstract][Full Text] [Related]
6. Effect of Variability of Physical Properties of Povidone K30 on Crystallization and Drug-Polymer Miscibility of Celecoxib-Povidone K30 Amorphous Solid Dispersions.
Phadke C; Sharma J; Sharma K; Bansal AK
Mol Pharm; 2019 Oct; 16(10):4139-4148. PubMed ID: 31454247
[TBL] [Abstract][Full Text] [Related]
7. Influence of Glass Forming Ability on the Physical Stability of Supersaturated Amorphous Solid Dispersions.
Blaabjerg LI; Bulduk B; Lindenberg E; Löbmann K; Rades T; Grohganz H
J Pharm Sci; 2019 Aug; 108(8):2561-2569. PubMed ID: 30878513
[TBL] [Abstract][Full Text] [Related]
8. Solubility advantage from amorphous etoricoxib solid dispersions.
Dani P; Puri V; Bansal AK
Drug Dev Ind Pharm; 2014 Jan; 40(1):92-101. PubMed ID: 23301771
[TBL] [Abstract][Full Text] [Related]
9. Myth or Truth: The Glass Forming Ability Class III Drugs Will Always Form Single-Phase Homogenous Amorphous Solid Dispersion Formulations.
Panini P; Rampazzo M; Singh A; Vanhoutte F; Van den Mooter G
Pharmaceutics; 2019 Oct; 11(10):. PubMed ID: 31614985
[TBL] [Abstract][Full Text] [Related]
10. Utilizing Drug Amorphous Solid Dispersions for the Preparation of Dronedarone per os Formulations.
Kapourani A; Manioudaki AE; Kontogiannopoulos KN; Barmpalexis P
Polymers (Basel); 2023 Nov; 15(21):. PubMed ID: 37959973
[TBL] [Abstract][Full Text] [Related]
11. Physicochemical properties of tadalafil solid dispersions - Impact of polymer on the apparent solubility and dissolution rate of tadalafil.
Wlodarski K; Sawicki W; Haber K; Knapik J; Wojnarowska Z; Paluch M; Lepek P; Hawelek L; Tajber L
Eur J Pharm Biopharm; 2015 Aug; 94():106-15. PubMed ID: 25998701
[TBL] [Abstract][Full Text] [Related]
12. Long-Term Physical (In)Stability of Spray-Dried Amorphous Drugs: Relationship with Glass-Forming Ability and Physicochemical Properties.
Edueng K; Bergström CAS; Gråsjö J; Mahlin D
Pharmaceutics; 2019 Aug; 11(9):. PubMed ID: 31438566
[TBL] [Abstract][Full Text] [Related]
13. Hydroxypropyl cellulose stabilizes amorphous solid dispersions of the poorly water soluble drug felodipine.
Sarode AL; Malekar SA; Cote C; Worthen DR
Carbohydr Polym; 2014 Nov; 112():512-9. PubMed ID: 25129775
[TBL] [Abstract][Full Text] [Related]
14. Determination of drug-polymer solubility from supersaturated spray-dried amorphous solid dispersions: A case study with Efavirenz and Soluplus®.
Costa BLA; Sauceau M; Del Confetto S; Sescousse R; Ré MI
Eur J Pharm Biopharm; 2019 Sep; 142():300-306. PubMed ID: 31247317
[TBL] [Abstract][Full Text] [Related]
15. Lacidipine Amorphous Solid Dispersion Based on Hot Melt Extrusion: Good Miscibility, Enhanced Dissolution, and Favorable Stability.
Xi L; Song H; Wang Y; Gao H; Fu Q
AAPS PharmSciTech; 2018 Oct; 19(7):3076-3084. PubMed ID: 30094722
[TBL] [Abstract][Full Text] [Related]
16. Investigating crystallization tendency, miscibility, and molecular interactions of drug-polymer systems for the development of amorphous solid dispersions.
Meng F; Paul SK; Borde S; Chauhan H
Drug Dev Ind Pharm; 2021 Apr; 47(4):579-608. PubMed ID: 33651659
[TBL] [Abstract][Full Text] [Related]
17. A Comparison of Spray-Drying and Co-Precipitation for the Generation of Amorphous Solid Dispersions (ASDs) of Hydrochlorothiazide and Simvastatin.
Myślińska M; Stocker MW; Ferguson S; Healy AM
J Pharm Sci; 2023 Aug; 112(8):2097-2114. PubMed ID: 36805392
[TBL] [Abstract][Full Text] [Related]
18. Five-Stage Approach for a Systematic Screening and Development of Etravirine Amorphous Solid Dispersions by Hot-Melt Extrusion.
Simões MF; Pereira A; Cardoso S; Cadonau S; Werner K; Pinto RMA; Simões S
Mol Pharm; 2020 Feb; 17(2):554-568. PubMed ID: 31774685
[TBL] [Abstract][Full Text] [Related]
19. Probing the mechanisms of drug release from amorphous solid dispersions in medium-soluble and medium-insoluble carriers.
Sun DD; Lee PI
J Control Release; 2015 Aug; 211():85-93. PubMed ID: 26054795
[TBL] [Abstract][Full Text] [Related]
20. Use of surfactants as plasticizers in preparing solid dispersions of poorly soluble API: stability testing of selected solid dispersions.
Ghebremeskel AN; Vemavarapu C; Lodaya M
Pharm Res; 2006 Aug; 23(8):1928-36. PubMed ID: 16871443
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
